TY - JOUR
T1 - Local anesthesia with general anesthesia for pediatric bone marrow procedures
AU - Zarnegar-Lumley, Sara
AU - Lange, Katharine R.
AU - Mathias, Melissa D.
AU - Nakajima-Hatano, Miho
AU - Offer, Katharine M.
AU - Ogu, Ugochi O.
AU - Ortiz, Michael V.
AU - Tan, Kay See
AU - Kellick, Michael
AU - Modak, Shakeel
AU - Roberts, Stephen S.
AU - Basu, Ellen M.
AU - Scott Dingeman, R.
N1 - Funding Information:
FUNDING: Funded in part through the National Institutes of Health (NIH) and National Cancer Institute (Cancer Center Support grant P30 CA008748). Dr Ortiz is supported by the NIH/National Cancer Institute (award K12CA184746). Funded by the National Institutes of Health (NIH).
Publisher Copyright:
Copyright © 2019 by the American Academy of Pediatrics
PY - 2019
Y1 - 2019
N2 - BACKGROUND: Pediatric patients with cancer undergo repeated painful procedures, including bone marrow aspirations and biopsies (BMABs). Optimal management of procedure-related pain can reduce discomfort, anxiety, and distress. METHODS: Children with neuroblastoma were randomly assigned to 1 of 2 arms on a prospective, single-blind, crossover trial conducted at Memorial Sloan Kettering Cancer Center from October 2016 to January 2018 (www.clinicaltrials.gov, identifier NCT02924324). Participants underwent 2 sequential BMABs: one with general anesthesia (GA) alone, the other with GA plus local anesthesia (LA) (GA 1 LA). The objective was to assess procedure-related pain and its interference with quality of life (QoL) with GA versus GA 1 LA. Primary outcome was percentage of participants requiring postprocedural opioids. Secondary outcomes were total opioid and nonopioid analgesics, pain scores, time to first analgesic, QoL, and toxicity. Management of postprocedural pain was standardized. RESULTS: Of 56 participants randomly assigned (3-16.5 years old), 46 completed both procedures. There was no significant difference in percentage of participants requiring opioids with GA versus GA 1 LA (24% vs 20%, P = .5). Pain scores in the recovery room were significantly lower for GA 1 LA versus GA (median [IQR]: 0 [0-2] vs 2 [0-4], P = .002). There were no statistically significant differences in total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference. No adverse events occurred. CONCLUSIONS: LA was associated with significant improvement in pain scores in the immediate recovery period. LA did not reduce postprocedural opioid use, nor did it improve QoL for patients undergoing BMAB with GA.
AB - BACKGROUND: Pediatric patients with cancer undergo repeated painful procedures, including bone marrow aspirations and biopsies (BMABs). Optimal management of procedure-related pain can reduce discomfort, anxiety, and distress. METHODS: Children with neuroblastoma were randomly assigned to 1 of 2 arms on a prospective, single-blind, crossover trial conducted at Memorial Sloan Kettering Cancer Center from October 2016 to January 2018 (www.clinicaltrials.gov, identifier NCT02924324). Participants underwent 2 sequential BMABs: one with general anesthesia (GA) alone, the other with GA plus local anesthesia (LA) (GA 1 LA). The objective was to assess procedure-related pain and its interference with quality of life (QoL) with GA versus GA 1 LA. Primary outcome was percentage of participants requiring postprocedural opioids. Secondary outcomes were total opioid and nonopioid analgesics, pain scores, time to first analgesic, QoL, and toxicity. Management of postprocedural pain was standardized. RESULTS: Of 56 participants randomly assigned (3-16.5 years old), 46 completed both procedures. There was no significant difference in percentage of participants requiring opioids with GA versus GA 1 LA (24% vs 20%, P = .5). Pain scores in the recovery room were significantly lower for GA 1 LA versus GA (median [IQR]: 0 [0-2] vs 2 [0-4], P = .002). There were no statistically significant differences in total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference. No adverse events occurred. CONCLUSIONS: LA was associated with significant improvement in pain scores in the immediate recovery period. LA did not reduce postprocedural opioid use, nor did it improve QoL for patients undergoing BMAB with GA.
UR - http://www.scopus.com/inward/record.url?scp=85071060900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071060900&partnerID=8YFLogxK
U2 - 10.1542/peds.2018-3829
DO - 10.1542/peds.2018-3829
M3 - Article
C2 - 31366683
AN - SCOPUS:85071060900
SN - 0031-4005
VL - 144
JO - Pediatrics
JF - Pediatrics
IS - 2
M1 - e20183829
ER -